Quaero Life Science Co., Ltd. (hereinafter referred to as Quaero) officially announced on December 24, 2024, that it has successfully signed a letter of intent with the well-known Japanese bio-medical enterprise Precision System Science Co., Ltd (hereinafter referred to as PSS Company) to establish a joint venture. This milestone cooperation signifies that both parties will jointly develop the global market in the fields of life sciences and IVD instrument CDMO.

PSS Company has nearly 40 years of experience in the IVD and life sciences CDMO industry, serving many top life sciences and in vitro diagnostic clients, with its magLEAD technology and Pathfast chemiluminescence analyzer highly praised. Quaero, as a leading enterprise in this field in China, has 19 years of industry experience and possesses a comprehensive engineering technology platform, software technology platform, and vertically integrated supply chain.

The joint venture will focus on the production and manufacturing of life science instruments and medical testing instruments in Japan, integrating the technology, market, brand, and supply chain resources of both parties to provide higher quality and diversified services. The joint venture has FDA audit experience, ISO13485 quality system certification, and a 4,000 square meter self-owned production base, bringing new business growth points for both parties.

This cooperation not only strengthens Quaero 's commitment to sustainable global market supply but also strategically targets the largest CDMO market in the world - Japan, which is of milestone significance for the company's development. Both parties will take this opportunity to deepen technical exchanges and cooperation, jointly develop more advanced products and services that meet market demands, enhance CDMO service quality, and meet the diverse needs of global customers.

Against the backdrop of increasing global economic uncertainty, the cooperation between Quaero and PSS Company demonstrates the firm confidence of both parties in the CDMO service market, setting a positive example for the industry. This deep cross-border cooperation model will elevate the international level of the industry and promote the continuous and healthy development of the bio-medical industry.

This cooperation is not only a strategic handshake at the corporate level but also a significant breakthrough in the field of global CDMO customer cooperation. It demonstrates the possibility of enhancing service quality and expanding market boundaries through cross-border cooperation and resource integration under the backdrop of globalization. We look forward to this cooperation bearing fruitful results and contributing to the development of the global medical diagnostics industry.

[Official PSS Release Link]:PSS 官方发布链接介绍.pdf

PSS Official Website: https://www.pss.co.jp/